Equities analysts expect R1 RCM Inc (NASDAQ:RCM) to report $315.75 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for R1 RCM’s earnings. The lowest sales estimate is $310.70 million and the highest is $320.80 million. R1 RCM posted sales of $262.90 million during the same quarter last year, which suggests a positive year-over-year growth rate of 20.1%. The company is expected to issue its next quarterly earnings report on Friday, February 28th.
On average, analysts expect that R1 RCM will report full-year sales of $1.19 billion for the current year, with estimates ranging from $1.18 billion to $1.19 billion. For the next fiscal year, analysts anticipate that the company will report sales of $1.36 billion, with estimates ranging from $1.33 billion to $1.39 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow R1 RCM.
R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.08). R1 RCM had a positive return on equity of 100.31% and a negative net margin of 0.13%. The business had revenue of $301.20 million during the quarter, compared to the consensus estimate of $302.85 million. During the same period last year, the company earned ($0.17) EPS. The business’s revenue was up 20.3% on a year-over-year basis.
RCM has been the topic of a number of research analyst reports. Robert W. Baird set a $14.00 price target on R1 RCM and gave the stock a “buy” rating in a research note on Thursday, September 12th. BidaskClub lowered shares of R1 RCM from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 17th. Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 27th. Finally, ValuEngine raised shares of R1 RCM from a “sell” rating to a “hold” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. R1 RCM presently has a consensus rating of “Buy” and a consensus price target of $11.75.
RCM traded up $0.17 on Thursday, hitting $12.83. 1,032,639 shares of the company’s stock traded hands, compared to its average volume of 1,016,872. The company’s 50 day simple moving average is $12.43 and its 200-day simple moving average is $11.66. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -40.09 and a beta of 0.18. R1 RCM has a one year low of $7.46 and a one year high of $13.19. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 29.28.
Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of R1 RCM by 38.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,817 shares of the healthcare provider’s stock worth $52,000 after buying an additional 1,625 shares in the last quarter. Virtu Financial LLC bought a new stake in R1 RCM in the 3rd quarter worth approximately $111,000. Aperio Group LLC bought a new stake in R1 RCM in the 2nd quarter worth approximately $127,000. NumerixS Investment Technologies Inc raised its holdings in shares of R1 RCM by 73.3% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 10,400 shares of the healthcare provider’s stock worth $131,000 after acquiring an additional 4,400 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of R1 RCM during the 2nd quarter worth approximately $139,000. Hedge funds and other institutional investors own 70.60% of the company’s stock.
R1 RCM Company Profile
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
Featured Article: Debt-To-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for R1 RCM and related companies with MarketBeat.com’s FREE daily email newsletter.